Search
for

    Learn

    5 / 33 results

      learn Stemoxydine

      chemical from L'Oreal that encourages hair to enter growth phase

      learn Adenosine

      nucleoside used for hair regrowth stimulant properties

      learn Exosomes

      Microscopic delivery system that sends growth-promoting signals to hair follicles

      learn Latanoprost

      glaucoma medication with hair follicle stimulant effects

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community How long are Pelage going to milk the phase 2a results of PP405?

      in Chat  21 upvotes 1 month ago
      PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

      community The expected timeline for PP405 - Next update at AAD Annual Meeting in March 2026 ?

      in Treatment  30 upvotes 2 months ago
      A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

      community My summation of PP405 - looks promising

      in Research/Science  209 upvotes 1 year ago
      PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

      community PP405 (Non) Update - Feb 2025

      in Research/Science  35 upvotes 11 months ago
      The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.